Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection

Clinical and Experimental Immunology

Volumn 131, Issue 1, 2003, Pages 122-129

  Harcourt, G C ^a   Lucas, M ^a   Godkin, A J ^b   Kantzanou, M ^a   Phillips, R E ^a   Klenerman, Paul ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

HCV genotype; Immune escape; MHC Class II; NS4; T helper cell

Indexed keywords

CD4 ANTIGEN; EPITOPE; NONSTRUCTURAL PROTEIN NS4; PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS REACTION; EPITOPE MAPPING; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE; VIRUS TYPING;

CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; EPITOPES; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HLA-A2 ANTIGEN; HUMANS;

EID: 0037234636     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02033.x     Document Type: Article

References (35)

1. Cohen J. The scientific challenge of Hepatitis C Virus. Science 1999; 285:26-30.
2. Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346:1006-7.
3. Gerlach JT, Diepolder HM, Jung MC et al. Recurrence of hepatitis C virus after loss of virus-specific CD4 (+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117:933-41.
4. Naoumov NV. Hepatitis C virus-specific CD4 (+) T cells: do they help or damage? [Editorial] Gastroenterology 1999; 117:1012-4.
5. Godkin A, Jeanguet N, Thurz M, Openshaw P, Thomas H. Characterisation of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. Eur J Immunology 2001; 31:1438-46.
6. Lechner F, Wong DK, Dunbar PR et al. Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus. J Exp Med 2000; 191:1499-512.
7. Planz O, Ehl S, Furrer E et al. A critical role for neutralising antibody-producing B cells, CD4+ cells and interferons in persistent infections of mice with LCMV. implications for adoptive immunotherapy of virus carriers. Proc Natl Acad Sci USA 1997; 94:6874-9.
8. Ciurea A, Hunziker L, Klenerman P, Hengartner H, Zinkernagel RM. Impairment of CD4 (+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J Exp Med 2001; 193:297-305.
9. Ferrari C, Valli A, Galati L et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19:286-95.
10. Lechmann M, Ihlenfeldt HG, Braunschweiger I et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996; 24:790-5.
11. Farci P, Shimoda A, Coiana A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339-44.
12. Harcourt GC, Garrard S, Davenport MP, Edwards A, Phillips RE. HIV-1 variation diminishes CD4 T lymphocyte recognition. J Exp Med 1998; 188:1785-93.
13. Rosenberg W. Mechanisms of immune escape in viral hepatitis. Gut 1999; 44:759-64.
14. Lamonaca V, Missale G, Urbani S et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4 (+) T cells: implications for vaccine development. Hepatology 1999; 30:1088-98.
15. Diepolder HM, Gerlach JT, Zachoval R et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71:6011-9.
16. Penna A, Missale G, Lamonaca V et al. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology 2002; 35:1225-36.
17. Harcourt G, Hellier S, Bunce M et al. Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat 2001; 8:174-9.
18. Bunce M, O'Neill CM, Barnardo MC et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46:355-67.
19. Forns X, Maluenda MD, Lopez-Labrador FX et al. Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. J Clin Microbiol 1996; 34:2516-21.
20. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. Rapid effector function in CD8+ memory T cells. J Exp Med 1997; 186:859-65.
21. Chang KM, Rehermann B, McHutchison JG et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997; 100:2376-85.
22. Godkin AJ, Davenport MP, Willis A, Jewell DP, Hill AV. Use of complete eluted peptide sequence data from HLA-DR and -DQ molecules to predict T cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection. J Immunol 1998; 161:850-8.
23. Davenport MP, Ho Shon IA, Hill AV. An empirical method for the prediction of T-cell epitopes. Immunogenetics 1995; 42:392-7.
24. Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128:195-203.
25. Barnes E, Harcourt G, Brown D et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002; 36:743-54.
26. McAdam S, Klenerman P, Tussey L et al. Immunogenic HIV variant peptides that bind to HLA-B8 can fail to stimulate cytotoxic T lymphocyte responses. J Immunol 1995; 155:2729-36.
27. Klenerman P, Meier UC, Phillips RE, McMichael AJ. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. European J Immunol 1995; 25:1927-31.
28. Laskus T, Wang LF, Radkowski M et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol 2001; 75:2059-66.
29. Proust B, Dubois F, Bacq Y et al. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol 2000; 38:3125-7.
30. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study. J Inf Dis 1999; 179:1062-9.
31. McElrath MJ, Corey L, Greenberg PD et al. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci USA 1996; 93:3972-7.
32. De St Groth F, Webster R. Disquisitions on original antigenic sin. I. Evidence in man. J Exp Med 1966; 124:331-45.
33. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998; 394:482-5.
34. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviours of acute HCV infection are associated with different vigor of the antiviral T cell response. J Clin Invest 1996; 98:706-14.
35. Lauer GM, Ouchi K, Chung RT et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76:6104-13.